Novartis AG NVS, a Swiss pharma giant, is scheduled to report first-quarter 2025 results on April 29, 2025. The Zacks ...

Novartis is set to invest $23 billion in US-based manufacturing and research and development (R&D) over the next five years, ...

Mid-sized Indian pharma firms revamp strategies amid US tariff concerns, focusing on NCDs, API manufacturing, emerging ...

Alembic Pharmaceuticals announced that it has received final approval from the U.S. Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Carbamazepine Tablets USP, ...

At the same time, drugmakers have come to rely on the U.S. market for the bulk of their revenue. In 2022, the U.S. accounted ...

Levies on Americans’ daily prescriptions and other medicines could raise costs, spur rationing and lead to shortages of ...

The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, ...

The moves, announced Monday in the Federal Register, are a precursor to imposing tariffs and threaten to broaden the president’s sweeping US trade war ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S.

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.